ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

SANDOSTATIN
Cytoprotective and supportive care agents
Pituitary disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

SANDOSTATIN Rx

Generic Name and Formulations:
Octreotide acetate 50mcg, 100mcg, 500mcg, 200mcg, 1000mcg; soln for IV or SC inj; contains mannitol, phenol (vials).

Company:
Novartis Pharmaceuticals Corp

e-Prescribe this drug via Surescripts


Therapeutic Use:

Indications for SANDOSTATIN:

Severe diarrhea and flushing due to metastatic carcinoid tumors. Profuse watery diarrhea due to vasoactive intestinal peptide-secreting tumors (VIPomas).

Adult Dose for SANDOSTATIN:

Give by IV infusion over 15–30 minutes, IV push over 3 minutes, or deep SC (intrafat) inj. Carcinoid tumors: 100–600mcg/day in 2–4 divided doses for first 2 weeks; usual maintenance: 450mcg/day; max 1500mcg/day. VIPomas: Initially 200–300mcg/day in 2–4 divided doses for first 2 weeks; max 750mcg/day.

Children's Dose for SANDOSTATIN:

Not recommended.

See Also:

SANDOSTATIN LAR DEPOT

Pharmacological Class:

Somatostatin analogue.

Warnings/Precautions:

Diabetes. Hypothyroidism. Cardiovascular disease. Renal or hepatic impairment. Carcinoid tumors: monitor 5-HIAA, plasma serotonin, plasma Substance P. VIPomas: perform baseline and periodic total and/or free T4 measurements with chronic therapy. Monitor thyroid function, gallbladder, glucose, vitamin B12. Pregnancy (Cat.B). Nursing mothers.

Interactions:

Potentiates bromocriptine, CYP450 substrates (eg, quinidine, terfenadine), bradycardia-inducing drugs (eg, β-blockers, calcium channel blockers). Antagonizes cyclosporine. Not compatible with TPN solutions. May need to adjust antidiabetic agents. May affect agents used to control fluid and electrolyte balance.

Adverse Reactions:

Gallbladder abnormalities (eg, gallstones, biliary sludge), GI upset, bradycardia, conduction abnormalities, arrhythmias, hyperglycemia, hypoglycemia, hypothyroidism, injection site pain, headache, dizziness, pancreatitis, altered dietary fat absorption.

How Supplied:

Ampules 50mcg/mL, 100mcg/mL, 500mcg/mL (1mL)—10
Multi-dose vials 200mcg/mL, 1000mcg/mL (5mL) —1
LAR kit—1 (5mL vial w. supplies)

Indications for SANDOSTATIN:

Acromegaly unresponsive to or that cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses.

Adult Dose for SANDOSTATIN:

Give by IV infusion over 15–30 minutes, IV push over 3 minutes, or deep SC (intrafat) inj. Initially 50mcg 3 times daily. Usual maintenance: 100micrograms 3 times daily; max 500mcg 3 times daily. Reevaluate every 6 months. Pituitary irradiation recipients: withdraw therapy for 4 weeks once yearly to assess disease activity; resume if GH or IGF-1 levels increase or signs/symptoms recur.

Children's Dose for SANDOSTATIN:

Not recommended.

See Also:

SANDOSTATIN LAR DEPOT

Pharmacological Class:

Somatostatin analogue.

Warnings/Precautions:

Diabetes. Hypothyroidism. Cardiovascular disease. Renal or hepatic impairment. Monitor growth hormone, IGF-1 levels, thyroid function, gallbladder, glucose, vitamin B12. Pregnancy (Cat.B). Nursing mothers.

Interactions:

Potentiates bromocriptine, CYP450 substrates (eg, quinidine, terfenadine), bradycardia-inducing drugs (eg, β-blockers, calcium channel blockers). Antagonizes cyclosporine. Not compatible with TPN solutions. May need to adjust antidiabetic agents. May affect agents used to control fluid and electrolyte balance.

Adverse Reactions:

Gallbladder abnormalities (eg, gallstones, biliary sludge), GI upset, bradycardia, conduction abnormalities, arrhythmias, hyperglycemia, hypoglycemia, hypothyroidism, injection site pain, headache, dizziness, pancreatitis, altered dietary fat absorption.

How Supplied:

Ampules 50mcg/mL, 100mcg/mL, 500mcg/mL (1mL)—10
Multi-dose vials 200mcg/mL, 1000mcg/mL (5mL) —1
LAR kit—1 (5mL vial w. supplies)

Sign Up for Free e-newsletters